Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Apr 10, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)," aims to better understand how blood flow to the brain is affected in patients who have experienced a subarachnoid hemorrhage (SAH), which is bleeding in the space around the brain. Researchers want to find out if the optimal blood flow pressure changes over time in these patients and whether the body's ability to regulate blood flow (called autoregulation) is disrupted, potentially leading to further complications like delayed cerebral ischemia (DCI), where parts of the brain do not get enough blood.

To participate in this study, individuals need to be between 18 and 89 years old and must be admitted to the Neurological Intensive Care Unit for treatment of an aneurysmal SAH between March 2025 and December 2026. Certain groups, like minors, pregnant women, or those involved in other clinical trials, will not be eligible. If you join the study, expect to have continuous monitoring of your brain's blood flow using a special device that measures light absorption in the brain. This research is important because it could help improve care for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 to 89 years who are admitted to the Neurological Intensive Care Unit (Neuro ICU) between March 2025 and December 2026 for aneurysmal subarachnoid hemorrhage (SAH).
• Exclusion Criteria:
• • Patients under 18 years old
• • Prisoners
• • Pregnant women
• • Patients enrolled in concurrent ongoing interventional trial
• • Students of UAB
• • Employees of UAB
• • Patients who undergoes frontal decompression surgery resulting bone flap deficit where NIRS monitoring pads could not be applied.